Trinity Biotech (TRIB) Share-based Compensation (IS) (2021 - 2024)

Trinity Biotech has disclosed Share-based Compensation (IS) across 4 years of filings, most recently posting $140000.0 for Q4 2024.

• Share-based Compensation (IS) for Q4 2024 came in at $140000.0, up 113.88% year-over-year; the trailing twelve-month figure through Dec 2024 was -$868012.0 (down 302.46% YoY), and the FY2024 annual result was $1.3 million, down 36.39% from the prior year.
• Share-based Compensation (IS) came in at $140000.0 for Q4 2024 at Trinity Biotech, up from $250.0 in the prior quarter.
• In the past five years, Share-based Compensation (IS) ranged from a high of $1.3 million in Q4 2022 to a low of -$1.0 million in Q4 2023.
• The 4-year median for Share-based Compensation (IS) is $738.0 (2023), against an average of $80380.2.
• Across the five-year window, Share-based Compensation (IS) surged 755.84% in 2022 and plunged 176.56% in 2023, its largest moves.
• Trinity Biotech's Share-based Compensation (IS) stood at $154000.0 in 2021, then soared by 755.84% to $1.3 million in 2022, then slumped by 176.56% to -$1.0 million in 2023, then jumped by 113.88% to $140000.0 in 2024.
• The last three Share-based Compensation (IS) figures came in at $140000.0 (Q4 2024), $250.0 (Q3 2024), and -$1.0 million (Q4 2023), per Business Quant data.